The University of Southampton
University of Southampton Institutional Repository

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

Record type: Article

Objective: to assess the efficacy and safety of galantamine in Alzheimer's disease at 3 months using flexible dose escalation.
Methods: a randomised, double blind, placebo controlled trial in 43 centres in the United States, Canada, Great Britain, South Africa, Australia, and New Zealand. Patients with probable Alzheimer's disease (n=386; 171 women) with a score of 11-24 on the mini mental state examination, and a score>= 12 on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog) were randomised to placebo, or galantamine escalated over 4 weeks to a maintenance dose of 24 or 32 mg/day. The primary outcome measures were the change in ADAS-cog score and the clinician's interview based impression of change plus caregiver input (CIBIC-plus) score. Activities of daily living (ADL) and behavioural symptoms were secondary outcomes. To compare the effects of highest levels of dosing, an observed cases (OC) analysis was undertaken, with classic intention to treat (ITT) and ITT with last observation carried forward (LOCF) as confirmatory analyses.
Results: at 3 months, galantamine (24-32 mg/day) produced a significantly better outcome on cognitive function than placebo (treatment difference=1.9 points on ADAS-cog, p=0.002) and a significantly better global response than placebo, as measured by CIBIC-plus (deterioration in 21% of patients on galantamine v 37% on placebo; p<0.001). Galantamine produced significant benefits on basic and instrumental ADL. Behavioural symptoms did not change significantly from baseline levels in either group. Adverse events (primarily gastrointestinal) were of mild to moderate intensity. There were no important differences between the OC, ITT, and ITT/LOCF analyses. Most patients (82%) who were maintained on the higher dose of galantamine completed the study.
Conclusions: patients on galantamine, compared with those on placebo, experienced benefits in cognitive function and instrumental and basic activities of daily living. Flexible dose escalation of galantamine was well tolerated.

Full text not available from this repository.

Citation

Rockwood, K., Mintzer, J., Truyen, L., Wessel, T. and Wilkinson, D. (2001) Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial Journal of Neurology, Neurosurgery, and Psychiatry, 71, (5), pp. 589-595.

More information

Published date: 2001
Keywords: Alzheimer's disease, galantamine, nicotinic receptors, acetylcholinesterase inhibition, activities of daily living

Identifiers

Local EPrints ID: 27702
URI: http://eprints.soton.ac.uk/id/eprint/27702
PURE UUID: d3abedeb-e67f-4080-a7bc-95a3f8ab6c11

Catalogue record

Date deposited: 27 Apr 2006
Last modified: 17 Jul 2017 16:04

Export record

Contributors

Author: K. Rockwood
Author: J. Mintzer
Author: L. Truyen
Author: T. Wessel
Author: D. Wilkinson

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×